$242 Million is the total value of SILVERARC CAPITAL MANAGEMENT, LLC's 72 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 61.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TERN | Sell | Terns Pharmaceuticals Incequities | $7,908,196 | +11.0% | 667,922 | -4.6% | 3.26% | +60.1% |
| Sell | Nuvalent Incequities | $7,345,196 | -18.6% | 281,533 | -7.1% | 3.03% | +17.5% | |
| BLU | Sell | Bellus Health Incequities | $7,200,000 | -48.7% | 1,000,000 | -41.4% | 2.97% | -26.0% |
| ITCI | Sell | Intra-Cellular Therapies Incequities | $6,770,645 | -8.9% | 125,035 | -10.9% | 2.80% | +31.5% |
| XENE | Sell | Xenon Pharmaceuticals Incequities | $3,458,853 | -65.4% | 96,643 | -61.9% | 1.43% | -50.1% |
| CERS | Sell | Cerus Corpequities | $3,424,119 | -42.6% | 1,152,902 | -29.4% | 1.41% | -17.2% |
| BIIB | Sell | Biogen Idec Incequities | $3,144,797 | -48.3% | 11,311 | -48.5% | 1.30% | -25.4% |
| ALNY | Sell | Alnylam Pharmaceuticals Incequities | $2,813,094 | -68.6% | 14,043 | -62.7% | 1.16% | -54.6% |
| KRYS | Sell | Krystal Biotech Incequities | $2,723,161 | -41.3% | 34,014 | -41.9% | 1.12% | -15.3% |
| PLRX | Sell | Pliant Therapeutics Incequities | $2,660,000 | -36.7% | 100,000 | -54.0% | 1.10% | -8.7% |
| MDGL | Sell | Madrigal Pharmaceuticals Incequities | $2,422,600 | -83.3% | 10,000 | -80.0% | 1.00% | -75.9% |
| MRSN | Sell | Mersana Therapeutics Incequities | $2,219,642 | -66.8% | 540,059 | -52.6% | 0.92% | -52.1% |
| IMTX | Sell | Immatics Nvequities | $1,948,781 | -49.1% | 282,432 | -35.8% | 0.80% | -26.6% |
| MORF | Sell | Morphic Holding Incequities | $1,945,386 | -78.3% | 51,684 | -84.6% | 0.80% | -68.6% |
| ACRS | Sell | Aclaris Therapeutics Incequities | $1,780,609 | -67.9% | 220,100 | -37.5% | 0.74% | -53.7% |
| RXDX | Sell | Prometheus Biosciences Incequities | $1,494,002 | -72.8% | 13,921 | -72.2% | 0.62% | -60.8% |
| PNT | Sell | Point Biopharma Global Incequities | $1,442,928 | -50.6% | 198,477 | -50.5% | 0.60% | -28.7% |
| MCRB | Sell | Seres Therapeutics Incequities | $1,318,417 | -37.1% | 232,525 | -37.9% | 0.54% | -9.3% |
| ALLK | Sell | Allakos Incequities | $938,995 | -76.8% | 211,010 | -56.1% | 0.39% | -66.5% |
| ABOS | Sell | Acumen Pharmaceuticals Incequities | $596,503 | -62.6% | 146,922 | -50.2% | 0.25% | -46.1% |
| IMGN | Sell | ImmunoGen Incequities | $576,000 | -71.5% | 150,000 | -63.2% | 0.24% | -58.8% |
| CVRX | Sell | Cvrx Incequities | $279,600 | -95.2% | 30,000 | -90.5% | 0.12% | -93.0% |
| CGEN | Sell | Compugen Ltdequities | $231,792 | -51.5% | 330,188 | -50.5% | 0.10% | -29.9% |
| LVTX | Sell | LAVA Therapeutics NVequities | $232,883 | -84.8% | 140,291 | -68.0% | 0.10% | -78.1% |
| MSACW | Exit | Medicus Sciences Acquisition Corpwarrants | $0 | – | -49,990 | -100.0% | -0.00% | – |
| EVGN | Exit | Evogene Ltdequities | $0 | – | -150,361 | -100.0% | -0.03% | – |
| GOSS | Exit | Gossamer Bio Incequities | $0 | – | -100,000 | -100.0% | -0.06% | – |
| QURE | Exit | Uniqure NVequities | $0 | – | -10,000 | -100.0% | -0.06% | – |
| PRAX | Exit | Praxis Precision Medicines Incequities | $0 | – | -98,409 | -100.0% | -0.07% | – |
| Exit | Braze Incequities | $0 | – | -10,000 | -100.0% | -0.08% | – | |
| WVE | Exit | WAVE Life Sciences Ltdequities | $0 | – | -50,000 | -100.0% | -0.10% | – |
| MGTX | Exit | Meiragtx Holdings Plcequities | $0 | – | -56,672 | -100.0% | -0.11% | – |
| IMUX | Exit | Immunic Incequities | $0 | – | -350,656 | -100.0% | -0.14% | – |
| DSGN | Exit | Design Therapeutics Incequities | $0 | – | -57,025 | -100.0% | -0.17% | – |
| CDXS | Exit | Codexis Incequities | $0 | – | -144,737 | -100.0% | -0.19% | – |
| STXS | Exit | Stereotaxis Incequities | $0 | – | -354,925 | -100.0% | -0.21% | – |
| AXSM | Exit | Axsome Therapeutics Incequities | $0 | – | -10,000 | -100.0% | -0.22% | – |
| CYTK | Exit | Cytokinetics Incequities | $0 | – | -17,500 | -100.0% | -0.23% | – |
| ALT | Exit | Altimmune Incequities | $0 | – | -50,546 | -100.0% | -0.24% | – |
| VERU | Exit | Veru Inc.put | $0 | – | -175,000 | -100.0% | -0.26% | – |
| AVXL | Exit | Anavex Life Science Corpcall | $0 | – | -102,600 | -100.0% | -0.27% | – |
| AVTE | Exit | Aerovate Therapeutics Incequities | $0 | – | -36,906 | -100.0% | -0.31% | – |
| CMPX | Exit | Compass Therapeutics Inc.equities | $0 | – | -268,307 | -100.0% | -0.39% | – |
| AMYT | Exit | Amryt Pharma PLCequities | $0 | – | -192,995 | -100.0% | -0.40% | – |
| SGEN | Exit | Seagen Incequities | $0 | – | -11,016 | -100.0% | -0.40% | – |
| CTIC | Exit | CTI BioPharma Corpequities | $0 | – | -254,361 | -100.0% | -0.44% | – |
| ISEE | Exit | IVERIC bio Incequities | $0 | – | -88,243 | -100.0% | -0.54% | – |
| HZNP | Exit | Horizon Therapeutics Plcequities | $0 | – | -23,054 | -100.0% | -0.75% | – |
| PHR | Exit | Phreesia Incequities | $0 | – | -85,390 | -100.0% | -0.79% | – |
| CRNX | Exit | Crinetics Pharmaceuticals Incequities | $0 | – | -152,747 | -100.0% | -0.80% | – |
| ASND | Exit | Ascendis Pharma A/Sequities | $0 | – | -23,151 | -100.0% | -0.81% | – |
| RNA | Exit | Avidity Biosciences Incequities | $0 | – | -128,000 | -100.0% | -0.81% | – |
| PCVX | Exit | Vaxcyte Incequities | $0 | – | -83,135 | -100.0% | -1.14% | – |
| PRTA | Exit | Prothena Corporation PLCequities | $0 | – | -71,706 | -100.0% | -1.24% | – |
| BCAB | Exit | Bioatla Incequities | $0 | – | -546,875 | -100.0% | -1.29% | – |
| Exit | GlaxoSmithKline PLCequities | $0 | – | -136,178 | -100.0% | -1.37% | – | |
| Exit | Cincor Pharma Incequities | $0 | – | -395,382 | -100.0% | -1.39% | – | |
| AKRO | Exit | Akero Therapeutics Inccall | $0 | – | -150,000 | -100.0% | -2.35% | – |
| AKRO | Exit | Akero Therapeutics Incput | $0 | – | -150,000 | -100.0% | -2.35% | – |
| MDGL | Exit | Madrigal Parmaceuticals, Inc.put | $0 | – | -30,000 | -100.0% | -2.49% | – |
| IMVT | Exit | Immunovant Incequities | $0 | – | -519,614 | -100.0% | -2.64% | – |
| AVXL | Exit | Anavex Life Science Corpput | $0 | – | -1,007,700 | -100.0% | -2.67% | – |
| RXDX | Exit | Prometheus Bioscience, Inc.put | $0 | – | -172,400 | -100.0% | -5.42% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- SilverArc Capital, LLC #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTRA-CELLULAR THERAPIES INC | 12 | Q3 2023 | 7.8% |
| IMMUNOGEN INC | 12 | Q3 2023 | 8.3% |
| Morphic Holding Inc | 12 | Q3 2023 | 4.5% |
| UNUM THERAPEUTICS INC | 12 | Q3 2023 | 3.2% |
| INSMED INC | 12 | Q3 2023 | 3.5% |
| UNITED THERAPEUTICS CORP DEL | 12 | Q3 2023 | 2.2% |
| MERUS N V | 11 | Q3 2023 | 5.1% |
| VERACYTE INC | 11 | Q3 2023 | 4.9% |
| EVOGENE LTD | 11 | Q3 2023 | 1.6% |
| COMPUGEN LTD | 11 | Q3 2023 | 1.1% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Benitec Biopharma Inc.Sold out | February 08, 2023 | 0 | 0.0% |
| DELCATH SYSTEMS, INC.Sold out | February 08, 2022 | 0 | 0.0% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G/A | 2023-02-08 |
| 13F-HR | 2022-10-28 |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.